Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > New poster
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Frogger2on Sep 25, 2014 12:22pm
202 Views
Post# 22969950

RE:RE:RE:RE:New poster

RE:RE:RE:RE:New poster
 
  1.  Also add clincal data publication in a high impact urology journal to expand KOL network and clinical support for MCNA approval as a near term catalyst.
 
  1. This along with Orphan drug status approval are near term and I believe will get us to a buck buy the new year.

Our previous management were not able to provide and publish legitimate clinical support data other than describing it as the golden goose.
  1.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities